Table 1.
Demographic and clinical characteristics of the sample
| Characteristic | Median | Mean ± SD | 95% CI (Mean) | Skewness | Kurtosis | CV |
|---|---|---|---|---|---|---|
| Age, y | 71 | 69.4 ± 9.9 | 68.0–70.7 | −0.5 | 0.2 | 0.1 |
| Education, y | 8.0 | 9.2 ± 4.7 | 8.6–9.8 | 0.6 | −0.5 | 0.5 |
| Disease duration, y | 7.0 | 7.7 ± 5.4 | 6.9–8.4 | 1.5 | 3.3 | 0.7 |
| Levodopa | ||||||
| Treatment duration, y | 5.0 | 6.0 ± 4.6 | 5.4–6.6 | 0.9 | 0.4 | 0.7 |
| Dose, mg/d | 750.0 | 716.9 ± 306.7 | 676.4–757.4 | −0.1 | 0.2 | 0.4 |
| SPES‐Scopa | ||||||
| Section 1 | 18.0 | 18.0 ± 5.5 | 17.3–18.7 | 0.2 | −0.5 | 0.3 |
| Section 2 | 8.0 | 9.2 ± 3.5 | 8.7–9.7 | 0.8 | 1.1 | 0.3 |
| Section 3 | 4.0 | 3.6 ± 2.9 | 3.2–4.0 | 0.5 | −0.4 | 0.8 |
| Total | 31 | 30.8 ± 10.9 | 29.4–32.2 | 0.5 | −0.1 | 0.3 |
| Schwab & England | 70.0 | 69.3 ± 15.0 | 67.3–71.3 | −1.1 | 1.3 | 0.2 |
| MMSE | 25.0 | 23.4 ± 4.9 | 22.7–24.0 | −1.9 | 5.2 | 0.2 |
| HADS | ||||||
| Anxiety | 6.0 | 7.3 ± 3.4 | 6.9–7.8 | 0.6 | −0.1 | 0.4 |
| Depression | 7.0 | 6.8 ± 3.7 | 6.3–7.3 | 0.4 | −0.5 | 0.5 |
| PIMS | 19.0 | 19.8 ± 9.4 | 18.5–21.0 | 0.1 | −0.6 | 0.4 |
| SCOPA‐Psychosocial | 9 | 10.2 ± 5.9 | 9.5–11.0 | 0.6 | −0.4 | 0.5 |
| PPRS | 1.0 | 1.5 ± 1.5 | 1.3–1.7 | 1.3 | 1.7 | 0.9 |
| CISI | 11.0 | 11.3 ± 4.4 | 10.8–11.9 | 0.6 | 0.5 | 0.3 |
| PD‐CRS | ||||||
| Subcortical | 51.6 | 51.5 ± 16.3 | 48.6–54.5 | −0.4 | 0.2 | 0.3 |
| Cortical | 24.4 | 24.4 ± 4.2 | 23.9–25.0 | −0.4 | −0.1 | 0.1 |
| Total | 76.0 | 76.0 ± 19.3 | 72.5–79.5 | −0.4 | 0.1 | 0.2 |
SD, standard deviation; CI, confidence interval; CV, coefficient of variation; SPES‐Scopa, Short Parkinson's Evaluation Scale‐Scales for Outcomes in Parkinson's Disease; MMSE, Mini‐Mental Status Examination; HADS, Hospital Anxiety and Depression Scale; PIMS, Parkinson's Impact Scale; SCOPA, Scales for Outcomes in Parkinson's Disease; PPRS, Parkinson's Psychosis Rating Scale; CISI, Clinical Impression of Severity Index; PD‐CRS, Parkinson's Disease Cognitive Rating Scale.